Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 -0.0516108852048796
Stock impact report

New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute

Revolution Medicines, Inc. (RVMD) 
Company Research Source: GlobeNewswire
REDWOOD CITY, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced its intention to support the Netherlands Cancer Institute (NKI) on a combination clinical study targeting two key nodes in the oncogenic RAS signaling pathway and to supply its investigational SHP2 inhibitor, RMC-4630, for this study. In addition, the American Association for Cancer Research (AACR) announced that the Pancreatic Cancer Collective, a strategic partnership of Stand Up To Cancer (SU2C) and the Lustgarten Foundation, has awarded up to $4 million in funding to researchers at the NKI to support the combination trial.  The Phase 1/1b trial would explore the combination of RMC-4630 with an investigational ERK inhibitor in solid tumors harboring RAS mutations with a focus on pancreatic cancer.  The AACR is the scientific partner of SU2C and has announce Show less Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
RVMD alerts

from News Quantified
Opt-in for
RVMD alerts

from News Quantified